ArticleFrontiers in pediatrics2023

Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study.

Nizar Mahlaoui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.